Work

Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.9062

Authors: Corey Carter, Yusuke Tomita, Akira Yuno, Jonathan Baker, Min-Jung Lee, Sunmin Lee, Scott Caroen, Mary Flanagan Quinn, Bryan Oronsky, Tony R. Reid, Pedro Cabrales, Nacer Abrouk, Jane B Trepel

Institutions: EpicentRx, Inc. (United States), National Institutes of Health, National Cancer Institute, University of California San Diego, Center for Cancer Research

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3030194207

Cites:

Cited by:

Related to: 10